KEMTUB012-NI2, a novel potent tubulysin analog that selectively targets hypoxic cancer cells and is potentiated by cytochrome p450 reductase downregulation
Hypoxia · 2017
DOI: 10.2147/hp.s132832 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hypoxia, 2017. Verfasst von Paolo Lazzari und 4 weiteren Autor:innen. Beteiligte Einrichtung: KemoTech s.r.l., Parco Scientifico della Sardegna, Pula, Cagliari. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- KemoTech s.r.l., Parco Scientifico della Sardegna, Pula, Cagliari.
- C.N.R. - Istituto di Chimica del Riconoscimento Molecolare, Sezione 'A. Quilico', Milano, Italy.
- Kosterlitz Centre for Therapeutics, Institute of Medical Sciences, University of Aberdeen.
- Aberdeen Biomedical Imaging Centre, Institute of Medical Sciences, Foresterhill, Aberdeen, Scotland, UK.
Zitieren
APA
Lazzari, P., Spiga, M., Sani, M., Zanda, M., & Fleming, I. N. (2017). KEMTUB012-NI2, a novel potent tubulysin analog that selectively targets hypoxic cancer cells and is potentiated by cytochrome p450 reductase downregulation. Hypoxia. https://doi.org/10.2147/hp.s132832
Vancouver
Lazzari P, Spiga M, Sani M, Zanda M, Fleming IN. KEMTUB012-NI2, a novel potent tubulysin analog that selectively targets hypoxic cancer cells and is potentiated by cytochrome p450 reductase downregulation. Hypoxia. 2017. doi:10.2147/hp.s132832
BibTeX
@article{Lazzari2017,
author = {Lazzari, Paolo and Spiga, Marco and Sani, Monica and Zanda, Matteo and Fleming, Ian N},
title = {KEMTUB012-NI2, a novel potent tubulysin analog that selectively targets hypoxic cancer cells and is potentiated by cytochrome p450 reductase downregulation},
journal = {Hypoxia},
year = {2017},
doi = {10.2147/hp.s132832}
}
EUVIMED